SecBot SecBot
8-K ·Filed Jun 29, 2026

PRAX

Praxis Precision Medicines, Inc.
BEARISH
Impact 6/10
Horizonmonths Processed4mo ago SEC0001689548-26-000069
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The 3-month PDUFA extension is a modest negative for near-term sentiment, but the absence of safety or manufacturing issues limits downside. Traders should watch for any FDA advisory committee announcement or additional data requests ahead of the new December 27, 2026 PDUFA date. The stock may trade on pipeline sentiment until the new decision date.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$334.79
T+0 close · Jun 29, 2026 · via day close
Latest settled
−15.73%
T+60 · $282.12
Vs SPY
−18.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $334.79entry
  2. T+1 · 5mo ago −4.54%α −4.40% · $319.60
  3. T+5 · 4mo ago −6.36%α −6.96% · $313.50
  4. T+20 · 4mo ago −5.67%α −4.64% · $315.80
  5. T+60 · 8w ago −15.73%α −18.55% · $282.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Praxis Precision Medicines announced a 3-month FDA extension of the PDUFA target action date for its relutrigine NDA (SCN2A/SCN8A DEEs) from September 27, 2026 to December 27, 2026, following the submission of additional sensitivity analyses deemed a major amendment. No new clinical studies were requested and no safety or manufacturing concerns were cited, but the delay introduces near-term uncertainty for the company's lead pipeline asset.

Key Facts

  • FDA extended PDUFA target action date for relutrigine NDA by 3 months to December 27, 2026
  • Extension triggered by submission of additional sensitivity analyses of existing clinical data, classified as a major amendment
  • No new clinical studies were requested and no safety or manufacturing concerns were cited
  • Review remains active and ongoing; company continues preparations for launch

Financial Impact

Delay of potential first commercial revenue by at least 3 months; no financial figures disclosed in filing

revenuetimeline

Risk Factors

  • Potential for further FDA delays or a complete response letter at the new PDUFA date
  • Competitive developments in DEE treatment landscape could erode market opportunity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001689548-26-000069
Document: 0001689548-26-000069-index-headers.html0001689548-26-000069
Document: 0001689548-26-000069-index.html0001689548-26-000069
Document: 0001689548-26-000069.txt0001689548-26-000069

Track record

16 reports on PRAX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +8.87% at T+20 after the Apr 6, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
  2. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  5. Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
  7. Jun 29, 202620w ago 8-K Bearish 6/10 Viewing Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
  9. Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
  10. May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026